ArticleJournal for immunotherapy of cancer2025

TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial.

Aung Naing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.